false 0001808898 0001808898 2024-03-06 2024-03-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 6, 2024

 

 

BENITEC BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39267   84-4620206

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

3940 Trust Way, Hayward, California   94545
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 780-0819

(Former Name or Former Address, if Changed Since Last Report): Not Applicable

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001   BNTC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Grants of Executive Stock Options. On March 6, 2024, the Compensation Committee of the Board of Directors of Benitec Biopharma Inc. (the “Company”) approved grants to Dr. Jerel Banks, Chief Executive Officer of the Company, and Megan Boston, Executive Director of the Company, of nonqualified stock options (the “Executive Options”) to purchase 466,554 and 200,004 shares, respectively, of the Company’s common stock pursuant to the Company’s 2020 Equity and Incentive Compensation Plan (the “Plan”). The Executive Options were granted at an exercise price of $5.21 per share, which equals the closing price of the Company’s common stock on March 6, 2024. The Executive Options will become vested and exercisable in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the applicable executive’s continued service with the Company through the applicable vesting date. Upon the occurrence of a Change in Control (as defined in the Plan) any unvested portion of the Executive Options will become fully-vested and exercisable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    BENITEC BIOPHARMA INC.
Date: March 8, 2024     By:  

/s/ Dr. Jerel A. Banks

    Name:   Dr. Jerel A. Banks
    Title:   Chief Executive Officer
v3.24.0.1
Document and Entity Information
Mar. 06, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001808898
Document Type 8-K
Document Period End Date Mar. 06, 2024
Entity Registrant Name BENITEC BIOPHARMA INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39267
Entity Tax Identification Number 84-4620206
Entity Address, Address Line One 3940 Trust Way
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code (510)
Local Phone Number 780-0819
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001
Trading Symbol BNTC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni Benitec Biopharma (NASDAQ:BNTC)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Benitec Biopharma
Grafico Azioni Benitec Biopharma (NASDAQ:BNTC)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Benitec Biopharma